JP2007514699A - （ａ）Ｎ−｛５−［４−（４−メチル−ピペラジノ−メチル）−ベンゾイルアミド］−２−メチルフェニル｝−４−（３−ピリジル）−２−ピリミジン−アミンおよび（ｂ）少なくとも１個のハイプシン化阻害剤を含む組み合わせ物およびその使用 - Google Patents

（ａ）Ｎ−｛５−［４−（４−メチル−ピペラジノ−メチル）−ベンゾイルアミド］−２−メチルフェニル｝−４−（３−ピリジル）−２−ピリミジン−アミンおよび（ｂ）少なくとも１個のハイプシン化阻害剤を含む組み合わせ物およびその使用 Download PDF

Info

Publication number
JP2007514699A
JP2007514699A JP2006544368A JP2006544368A JP2007514699A JP 2007514699 A JP2007514699 A JP 2007514699A JP 2006544368 A JP2006544368 A JP 2006544368A JP 2006544368 A JP2006544368 A JP 2006544368A JP 2007514699 A JP2007514699 A JP 2007514699A
Authority
JP
Japan
Prior art keywords
combination
leukemia
methyl
imatinib
hypusination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006544368A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007514699A5 (https=
Inventor
ティム・ハー・ブリューメンドルフ
シュテファン・バラバノフ
ウルリケ・ハルトマン
ヴィンフリート・カンマー
アルフレート・ノルトハイム
Original Assignee
ノバルティス アクチエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アクチエンゲゼルシャフト filed Critical ノバルティス アクチエンゲゼルシャフト
Publication of JP2007514699A publication Critical patent/JP2007514699A/ja
Publication of JP2007514699A5 publication Critical patent/JP2007514699A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2006544368A 2003-12-19 2004-12-17 （ａ）Ｎ−｛５−［４−（４−メチル−ピペラジノ−メチル）−ベンゾイルアミド］−２−メチルフェニル｝−４−（３−ピリジル）−２−ピリミジン−アミンおよび（ｂ）少なくとも１個のハイプシン化阻害剤を含む組み合わせ物およびその使用 Pending JP2007514699A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53156303P 2003-12-19 2003-12-19
PCT/EP2004/014439 WO2005058320A1 (en) 2003-12-19 2004-12-17 COMBINATION OF (a) N-{5-[4-(4-METHYL-PIPERAZINO-METHYL)-BENZOYLAMIDO]-2METHYLPHENYL}-4-(3-PYRIDYL)-2-PYRIMIDINE-AMINE AND (b) AT LEAST ONE HYPUSINATION INHIBITOR AND THE USE THEREOF

Publications (2)

Publication Number Publication Date
JP2007514699A true JP2007514699A (ja) 2007-06-07
JP2007514699A5 JP2007514699A5 (https=) 2008-02-07

Family

ID=34700180

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006544368A Pending JP2007514699A (ja) 2003-12-19 2004-12-17 （ａ）Ｎ−｛５−［４−（４−メチル−ピペラジノ−メチル）−ベンゾイルアミド］−２−メチルフェニル｝−４−（３−ピリジル）−２−ピリミジン−アミンおよび（ｂ）少なくとも１個のハイプシン化阻害剤を含む組み合わせ物およびその使用

Country Status (17)

Country Link
US (1) US20080139480A1 (https=)
EP (1) EP1696917A1 (https=)
JP (1) JP2007514699A (https=)
KR (1) KR20060125810A (https=)
CN (1) CN1889952A (https=)
AU (2) AU2004298761A1 (https=)
BR (1) BRPI0417759A (https=)
CA (1) CA2547196A1 (https=)
EC (1) ECSP066656A (https=)
IL (1) IL176070A0 (https=)
MA (1) MA28240A1 (https=)
MX (1) MXPA06006925A (https=)
NO (1) NO20063326L (https=)
RU (1) RU2006125741A (https=)
TN (1) TNSN06182A1 (https=)
WO (1) WO2005058320A1 (https=)
ZA (1) ZA200603904B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013528619A (ja) * 2010-06-01 2013-07-11 ビオトヘルイク， インコーポレイテッド ヒドロキシピリドン誘導体、その医薬組成物、及び増殖性疾患治療のためのその治療的使用
JP2013528620A (ja) * 2010-06-01 2013-07-11 ビオトヘルイク， インコーポレイテッド ６−シクロヘキシル−１−ヒドロキシ−４−メチル−２（１ｈ）−ピリドンを使用する血液悪性疾患の治療方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2197440B1 (en) 2007-08-31 2012-12-26 Janssen Pharmaceutica, N.V. Combinations of imazalil and hydroxypyridones
WO2009036753A2 (de) * 2007-09-20 2009-03-26 Schebo Biotech Ag Neue pharmazeutika, verfahren zu ihrer herstellung und ihre verwendung in der medizinischen therapie
US8575187B2 (en) 2008-02-06 2013-11-05 Janssen Pharmaceutica, Nv Combinations of anilinopyrimidines and pyrion compounds
CA2711762C (en) 2008-02-06 2016-11-01 Jan Pieter Hendrik Bosselaers Combinations of phenylpyrroles and pyrion compounds
WO2010048712A1 (en) * 2008-10-31 2010-05-06 University Health Network Ciclopirox and cytarabine for the treatment of leukemic disorders
CN102917591B (zh) 2010-06-10 2014-07-23 詹森药业有限公司 嘧霉胺和单萜烯的组合
EP2587920B1 (en) 2010-07-01 2016-08-10 Janssen Pharmaceutica, N.V. Antimicrobial combinations of pyrion compounds with polyethyleneimines
CN103191110A (zh) * 2013-03-28 2013-07-10 中国科学院昆明植物研究所 环吡酮及环吡酮胺在制备防治黑色素瘤的药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62223130A (ja) * 1985-11-25 1987-10-01 ザ　ホスピタル　フオ−　シツク　チルドレン 複合治療剤，その製造方法及び製剤又は製剤パツク
JP2000507601A (ja) * 1996-06-25 2000-06-20 ノバルティス アクチエンゲゼルシャフト 置換３，５―ジフェニル―１，２，４―トリアゾールおよび製薬的金属キレート化剤としてのその使用
WO2002076476A2 (en) * 2001-03-23 2002-10-03 Enzon, Inc. Prodrugs of anticancer agents employing substituted aromatic acids

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0227593A1 (en) * 1985-11-25 1987-07-01 The Hospital For Sick Children Use of chelating agents
AU2003251875A1 (en) * 2002-07-15 2004-02-02 Combinatorx, Incorporated Combination therapy for the treatment of neoplasms

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62223130A (ja) * 1985-11-25 1987-10-01 ザ　ホスピタル　フオ−　シツク　チルドレン 複合治療剤，その製造方法及び製剤又は製剤パツク
JP2000507601A (ja) * 1996-06-25 2000-06-20 ノバルティス アクチエンゲゼルシャフト 置換３，５―ジフェニル―１，２，４―トリアゾールおよび製薬的金属キレート化剤としてのその使用
WO2002076476A2 (en) * 2001-03-23 2002-10-03 Enzon, Inc. Prodrugs of anticancer agents employing substituted aromatic acids

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013528619A (ja) * 2010-06-01 2013-07-11 ビオトヘルイク， インコーポレイテッド ヒドロキシピリドン誘導体、その医薬組成物、及び増殖性疾患治療のためのその治療的使用
JP2013528620A (ja) * 2010-06-01 2013-07-11 ビオトヘルイク， インコーポレイテッド ６−シクロヘキシル−１−ヒドロキシ−４−メチル−２（１ｈ）−ピリドンを使用する血液悪性疾患の治療方法

Also Published As

Publication number Publication date
MA28240A1 (fr) 2006-10-02
CN1889952A (zh) 2007-01-03
NO20063326L (no) 2006-09-19
RU2006125741A (ru) 2008-01-27
EP1696917A1 (en) 2006-09-06
ECSP066656A (es) 2006-10-25
KR20060125810A (ko) 2006-12-06
US20080139480A1 (en) 2008-06-12
BRPI0417759A (pt) 2007-04-10
TNSN06182A1 (en) 2007-11-15
AU2009201694A1 (en) 2009-05-28
AU2004298761A1 (en) 2005-06-30
IL176070A0 (en) 2006-10-05
MXPA06006925A (es) 2006-08-23
CA2547196A1 (en) 2005-06-30
ZA200603904B (en) 2007-09-26
WO2005058320A1 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
AU2009201694A1 (en) Combination of (a) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and (b) at least one hypusination inhibitor and the use thereof
Cicenas et al. Roscovitine in cancer and other diseases
Sun et al. Activation of the p62‐Keap1‐NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells
EP1250140B1 (en) Combination ofan abl-, pdgf-receptor- and/or kit receptor-tyrosine kinase inhibitor with an organic compound capable of binding to alpha1-acidic glycoprotein
JP6532878B2 (ja) 組合せ医薬
US9421208B2 (en) Methods for the treatment of solid tumors
Lara Jr et al. The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial
CN116019921A (zh) 用于治疗癌症的组合疗法
Zhang et al. Silibinin-induced glioma cell apoptosis by PI3K-mediated but Akt-independent downregulation of FoxM1 expression
US9533969B2 (en) Materials and method for inhibiting replication protein A and uses thereof
US20110281902A1 (en) Combinations comprising a protein kinase inhibitor being a pyrimidylaminobenzamide compound and a hsp90 inhibitor such as 17-aag
JP2022539840A (ja) Ｍａｐキナーゼ相互作用セリン／スレオニン－プロテインキナーゼ１（ｍｎｋ１）及びｍａｐキナーゼ相互作用セリン／スレオニン－プロテインキナーゼ２（ｍｎｋ２）の阻害剤、癌治療及び治療的組合せ
Durrant et al. Targeted inhibition of phosphoinositide 3-kinase/mammalian target of rapamycin sensitizes pancreatic cancer cells to doxorubicin without exacerbating cardiac toxicity
US12570668B2 (en) Single molecule compounds providing multi-target inhibition of BTK and other proteins and methods of use thereof
RU2445960C2 (ru) Применение производных пиримидиламинобензамида для лечения системного мастоцитоза
US20130310352A1 (en) Dexamethasone combination therapy
US20220409582A1 (en) Combination therapies comprising panobinostat for the treatment of cholangiocarcinoma
KR20080044277A (ko) 유기 화합물의 조합물
RU2850269C2 (ru) Фармацевтические комбинации для лечения злокачественной опухоли
Ahmad et al. Venetoclax (Venclexta): A BCL‐2 Antagonist for Treating Chronic Lymphocytic Leukemia
US20210128683A1 (en) Pharmaceutical compositions and use thereof for relieving resistance due to cancer chemotherapy and enhancing effect of cancer chemotherapy
WO2021048418A1 (en) Combination therapies comprising bortezomib for the treatment of cholangiocarcinoma
JP2009502995A (ja) ＩＫＫ−β阻害剤による腫瘍の処置

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071211

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071211

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110125

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110705